Can Anti-Parasitic Drugs Help Control COVID-19?

References

• WHO . COVID-19: One year later – WHO Director-General’s new year message. http://www.who.int/News/Item/30-12-2020-COVID-19-Anniversary-and-Looking-Forward-to-2021
   Google Scholar
• The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 5(4), 536–544 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng J , WangX, NieTet al. A novel electrochemical sensing platform for detection of dopamine based on gold nanobipyramid/multi-walled carbon nanotube hybrids. Anal. Bioanal. Chem., 412(11), 2433–2441 (2020).
   PubMed Web of Science ®Google Scholar
• Boopathi S , PomaAB, KolandaivelP. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J. Biomol. Struct. Dyn., 39(9), 3409–3418 (2021).
   PubMed Web of Science ®Google Scholar
• Hui DSC , ZumlaA. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am., 33(4), 869–889 (2019).
   PubMed Web of Science ®Google Scholar
• Guo ZD , WangZY, ZhangSFet al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. Emerg. Infect. Dis., 26(7), 1583–1591 (2020).
   PubMed Web of Science ®Google Scholar
• Khateeb J , LiY, ZhangH. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit. Care, 25(1), 244 (2021).
   PubMed Web of Science ®Google Scholar
• Li Z , NieK, LiKet al. Genome characterization of the first outbreak of COVID-19 Delta Variant B.1.617.2 - Guangzhou City, Guangdong Province, China, May 2021. China CDC Wkly, 3(27), 587–589 (2021).
   PubMedGoogle Scholar
• Alexandar SRM , KumarRs, JakkanK. . A comprehensive review on COVID-19 Delta variant. Int. J. Pharmacol. Clin. Res., 5, 83–85 (2021).
   Google Scholar
• Planas D , VeyerD, BaidaliukAet al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 596(7871), 276–280 (2021).
   PubMed Web of Science ®Google Scholar
• Geng J , ChenL, YuanYet al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants Delta, Alpha, Beta, and Gamma. Signal. Transduct. Target Ther., 6(1), 347 (2021).
   PubMed Web of Science ®Google Scholar
• An EUA for sotrovimab for treatment of COVID-19. Med. Lett. Drugs Ther., 63(1627), 97–98 (2021).
   PubMed Web of Science ®Google Scholar
• Li M , LouF, FanH. SARS-CoV-2 variants of concern Delta: a great challenge to prevention and control of COVID-19. Signal. Transduct. Target Ther., 6(1), 349 (2021).
   PubMed Web of Science ®Google Scholar
• Desai AN , MajumderMS. What is herd immunity?JAMA, 324(20), 2113 (2020).
   PubMedGoogle Scholar
• Papachristodoulou E , KakoullisL, ParperisK, PanosG. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge. Pathog. Dis., 78(3), (2020).
   PubMed Web of Science ®Google Scholar
• Matin S , TaleiS, DalimiA, DadkhahM, GhorbaniM, MolaeiS. COVID-19 and hydatidosis infections: is there any relationship?Iran J. Parasitol., 16(2), 343–345 (2021).
   PubMed Web of Science ®Google Scholar
• Paraskevis D , KostakiEG, MagiorkinisG, PanayiotakopoulosG, SourvinosG, TsiodrasS. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol., 79, 104212 (2020).
   PubMed Web of Science ®Google Scholar
• Mousavizadeh L , GhasemiS. Genotype and phenotype of COVID-19: their roles in pathogenesis. J. Microbiol. Immunol. Infect., 54(2), 159–163 (2021).
   PubMedGoogle Scholar
• Chen Y , LiuQ, GuoD. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol., 92(4), 418–423 (2020).
   PubMed Web of Science ®Google Scholar
• Kumar SNR , MauryaVKSaxenaSK. Coronavirus disease 2019 (COVID-19), epidemiology, pathogenesis, diagnosis, and therapeutics. In: Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).SaxenaSK ( Ed.). Centre for Advanced Research, King George’s Medical University, Lucknow, India, 23–31 (2020).
   Google Scholar
• Wu A , PengY, HuangBet al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe, 27(3), 325–328 (2020).
   PubMed Web of Science ®Google Scholar
• Perlman S , NetlandJ. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol., 7(6), 439–450 (2009).
   PubMed Web of Science ®Google Scholar
• Maier HJ , BickertonE, BrittonP. Preface. Coronaviruses. Methods Mol. Biol.1282 v (2015).
   PubMedGoogle Scholar
• Wen F , YuH, GuoJ, LiY, LuoK, HuangS. Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2. J. Infect., 80(6), 671–693 (2020).
   PubMed Web of Science ®Google Scholar
• Lou J , TianSJ, NiuSMet al. Coronavirus disease 2019: a bibliometric analysis and review. Eur. Rev. Med. Pharmacol. Sci., 24(6), 3411–3421 (2020).
   PubMed Web of Science ®Google Scholar
• Schoeman D , FieldingBC. Coronavirus envelope protein: current knowledge. Virol J., 16(1), 69 (2019).
   PubMed Web of Science ®Google Scholar
• Salata C , CalistriA, AlvisiG, CelestinoM, ParolinC, PalùG. Ebola virus entry: from molecular characterization to drug discovery. Viruses, 11(3), 274 (2019).
   PubMed Web of Science ®Google Scholar
• Delvecchio R , HigaLM, PezzutoPet al. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses, 8(12), 322 (2016).
   PubMed Web of Science ®Google Scholar
• Omotade TO , RoyCR. Manipulation of host cell organelles by intracellular pathogens. Microbiol. Spectr., 7(2), 6484 (2019).
   Web of Science ®Google Scholar
• Praveen D , ChowdaryPR, AanandhiMV. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int. J. Antimicrob. Agents, 55(5), 105967 (2020).
   PubMed Web of Science ®Google Scholar
• Algaissi A , HashemAM. Evaluation of MERS-CoV neutralizing antibodies in sera using live virus microneutralization assay. Methods Mol. Biol., 2099, 107–116 (2020).
   PubMedGoogle Scholar
• Goo J , JeongY, ParkYSet al. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. Virus Res., 278, 197863 (2020).
   PubMed Web of Science ®Google Scholar
• Pinto D , ParkYJ, BeltramelloMet al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 583(7815), 290–295 (2020).
   PubMed Web of Science ®Google Scholar
• Hijikata A , Shionyu-MitsuyamaC, NakaeSet al. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs. FEBS Lett., 594(12), 1960–1973 (2020).
   PubMed Web of Science ®Google Scholar
• Mirza MU , FroeyenM. Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J. Pharm. Anal., 10(4), 320–328 (2020).
   PubMed Web of Science ®Google Scholar
• Saha P , BanerjeeAK, TripathiPP, SrivastavaAK, RayU. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of coronavirus COVID-19 might impact receptor binding, and thus, infectivity. Biosci. Rep., 40(5), (2020).
   PubMedGoogle Scholar
• Meyer D , SielaffF, HammamiM, Böttcher-FriebertshäuserE, GartenW, SteinmetzerT. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem. J., 452(2), 331–343 (2013).
   PubMed Web of Science ®Google Scholar
• Wrapp D , WangN, CorbettKSet al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263 (2020).
   PubMed Web of Science ®Google Scholar
• Hoffmann M , Kleine-WeberH, SchroederSet al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e278 (2020).
   PubMed Web of Science ®Google Scholar
• Rahman N , BasharatZ, YousufM, CastaldoG, RastrelliL, KhanH. Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules, 25(10), 2271 (2020).
   PubMed Web of Science ®Google Scholar
• Shirato K , KawaseM, MatsuyamaS. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol., 87(23), 12552–12561 (2013).
   PubMed Web of Science ®Google Scholar
• Sternberg A , MckeeDL, NaujokatC. Novel drugs targeting the SARS-CoV-2/COVID-19 machinery. Curr. Top. Med. Chem., 20(16), 1423–1433 (2020).
   PubMed Web of Science ®Google Scholar
• Cao YC , DengQX, DaiSX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med. Infect. Dis., 35, 101647 (2020).
   PubMed Web of Science ®Google Scholar
• Gordon CJ , TchesnokovEP, FengJY, PorterDP, GötteM. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem., 295(15), 4773–4779 (2020).
   PubMed Web of Science ®Google Scholar
• Mcbride R , Van ZylM, FieldingBC. The coronavirus nucleocapsid is a multifunctional protein. Viruses, 6(8), 2991–3018 (2014).
   PubMed Web of Science ®Google Scholar
• Sarma P , ShekharN, PrajapatMet al. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J. Biomol. Struct. Dyn., 39(8), 2724–2732 (2021).
   PubMed Web of Science ®Google Scholar
• Bojkova D , KlannK, KochBet al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature, 583(7816), 469–472 (2020).
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN , CottrellCA, WangNet al. Pre-fusion structure of a human coronavirus spike protein. Nature, 531(7592), 118–121 (2016).
   PubMed Web of Science ®Google Scholar
• Gupta MK , VemulaS, DondeR, GoudaG, BeheraL, VaddeR. In silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. J. Biomol. Struct. Dyn., 39(7), 2617–2627 (2021).
   PubMed Web of Science ®Google Scholar
• Lundberg L , PinkhamC, BaerAet al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res., 100(3), 662–672 (2013).
   PubMed Web of Science ®Google Scholar
• Tu YF , ChienCS, YarmishynAAet al. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 21(7), 2657 (2020).
   PubMed Web of Science ®Google Scholar
• Caly L , DruceJD, CattonMG, JansDA, WagstaffKM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 178, 104787 (2020).
   PubMed Web of Science ®Google Scholar
• Rezaee H , PourkarimF, Pourtaghi-AnvarianS, Entezari-MalekiT, Asvadi-KermaniT, Nouri-VaskehM. Drug-drug interactions with candidate medications used for COVID-19 treatment: an overview. Pharmacol. Res. Perspect., 9(1), e00705 (2021).
   PubMed Web of Science ®Google Scholar
• Talukdar D , JainV, BalaramnavarV, SrivastavaSP, SivanandP, GuptaMM. Potential drugs for COVID-19 treatment management with their contraindications and drug-drug interaction. Preprintshttps://doi.org/10.20944/preprints202105.0690.v1 (2021) ( Epub ahead of print).
   Google Scholar
• Yang K . What do we know about remdesivir drug interactions?Clin. Transl. Sci., 13(5), 842–844 (2020).
   PubMed Web of Science ®Google Scholar
• Kumar D , TrivediN. Disease-drug and drug-drug interaction in COVID-19: risk and assessment. Biomed. Pharmacother., 139, 111642 (2021).
   PubMed Web of Science ®Google Scholar
• Hashem AM , AlghamdiBS, AlgaissiAAet al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review. Travel Med. Infect. Dis., 35, 101735 (2020).
   PubMed Web of Science ®Google Scholar
• Sachdeva C , WadhwaA, KumariA, HussainF, JhaP, KaushikNK. In silico potential of approved antimalarial drugs for repurposing against COVID-19. Omics, 24(10), 568–580 (2020).
   PubMed Web of Science ®Google Scholar
• Weniger H , World Health Organization. Review of side effects and toxicity of chloroquine / by H. Weniger. (WHO/MAL/79.906) (1979). https://apps.who.int/iris/handle/10665/65773
   Google Scholar
• Goel PGV . Chloroquine. StatPearls Publishing, FL, USA (2019).
   Google Scholar
• Freedman A , SteinbergVL. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann. Rheum. Dis., 19(3), 243–250 (1960).
   PubMed Web of Science ®Google Scholar
• Biot C , DaherW, ChavainNet al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem., 49(9), 2845–2849 (2006).
   PubMed Web of Science ®Google Scholar
• Colson P , RolainJM, LagierJC, BrouquiP, RaoultD. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob. Agents, 55(4), 105932 (2020).
   PubMed Web of Science ®Google Scholar
• Pahan P , PahanK. Smooth or risky revisit of an old malaria drug for COVID-19?J. Neuroimmune Pharmacol., 15(2), 174–180 (2020).
   PubMed Web of Science ®Google Scholar
• Vincent MJ , BergeronE, BenjannetSet al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2, 69 (2005).
   PubMed Web of Science ®Google Scholar
• Wang N , HanS, LiuRet al. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. Phytomedicine, 79, 153333 (2020).
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E , DörnerT. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol., 16(3), 155–166 (2020).
   PubMed Web of Science ®Google Scholar
• Rainsford KD , ParkeAL, Clifford-RashotteM, KeanWF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology, 23(5), 231–269 (2015).
   PubMed Web of Science ®Google Scholar
• Roche PA , FurutaK. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol., 15(4), 203–216 (2015).
   PubMed Web of Science ®Google Scholar
• Khatooni EBF , AbdiZ. Safety and efficacy of hydroxychloroquine and chloroquine in treatment of COVID-19: a rapid review of evidence. Health Tech. Asmnt. Act, 4(1), e5864 (2020).
   Google Scholar
• Pereira BB . Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. J. Toxicol. Environ. Health B Crit. Rev., 23(4), 177–181 (2020).
   PubMed Web of Science ®Google Scholar
• Liu J , CaoR, XuMet al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov., 6, 16 (2020).
   PubMed Web of Science ®Google Scholar
• Naghipour S , GhodousiM, RahseparS, ElyasiS. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-19. Expert Rev. Anti Infect. Ther., 18(11), 1119–1133 (2020).
   PubMed Web of Science ®Google Scholar
• Savarino A , DiTrani L, DonatelliI, CaudaR, CassoneA. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis., 6(2), 67–69 (2006).
   PubMed Web of Science ®Google Scholar
• Wang M , CaoR, ZhangLet al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 30(3), 269–271 (2020).
   PubMed Web of Science ®Google Scholar
• Yao X , YeF, ZhangMet al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 71(15), 732–739 (2020).
   PubMed Web of Science ®Google Scholar
• Huang M , LiM, XiaoFet al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci. Rev., 7(9), 1428–1436 (2020).
   PubMed Web of Science ®Google Scholar
• Borba MDaVF , SampaioVs, AlexandreMaet al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, Phase IIb clinical trial (CloroCOVID-19 study). MedRxivhttps://doi.org/10.1101/2020.04.07.20056424 (2020) ( Epub ahead of print).
   Google Scholar
• Lee SH , SonH, PeckKR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?Int. J. Antimicrob. Agents, 55(6), 105988 (2020).
   PubMed Web of Science ®Google Scholar
• Ullah W , AbdullahHM, RoomiSet al. Safety and efficacy of hydroxychloroquine in COVID-19: a systematic review and meta-analysis. J. Clin. Med. Res., 12(8), 483–491 (2020).
   PubMedGoogle Scholar
• Cortegiani A , IngogliaG, IppolitoM, GiarratanoA, EinavS. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care, 57, 279–283 (2020).
   PubMed Web of Science ®Google Scholar
• Patil VM , SinghalS, MasandN. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: efficacy, safety and clinical trials. Life Sci., 254, 117775 (2020).
   PubMed Web of Science ®Google Scholar
• Saghir SaM , AlgabriNA, AlagawanyMMet al. Chloroquine and hydroxychloroquine for the prevention and treatment of COVID-19: a fiction, hope or hype? An updated review. Ther. Clin. Risk Manag., 17, 371–387 (2021).
   PubMed Web of Science ®Google Scholar
• Chen J , LiuD, LiuLet al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban, 49(2), 215–219 (2020).
   PubMedGoogle Scholar
• Yu B , LiC, ChenPet al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci. China Life Sci., 63(10), 1515–1521 (2020).
   PubMed Web of Science ®Google Scholar
• Chowdhury AT , ShahbazM, KarimR, IslamJ, GuoD, HeS. A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients. EJMO, 5(1), 63–70 (2020).
   Google Scholar
• Gao J , TianZ, YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends, 14(1), 72–73 (2020).
   PubMed Web of Science ®Google Scholar
• Spinelli FR , CeccarelliF, DiFranco M, ContiF. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic. Ann. Rheum. Dis., 79(5), 666–667 (2020).
   PubMed Web of Science ®Google Scholar
• Chen ZHJ , ZhangZ, JiangSet al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Medrxivhttps://doi.org/10.1101/2020.03.22.20040758 (2020) ( Epub ahead of print).
   Google Scholar
• Fossa AA , WisialowskiT, DuncanJN, DengS, DunneM. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am. J. Trop. Med. Hyg., 77(5), 929–938 (2007).
   PubMed Web of Science ®Google Scholar
• Gautret P , LagierJC, ParolaPet al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 56(1), 105949 (2020).
   PubMed Web of Science ®Google Scholar
• Fiolet T , GuihurA, RebeaudME, MulotM, Peiffer-SmadjaN, Mahamat-SalehY. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin. Microbiol. Infect., 27(1), 19–27 (2021).
   PubMed Web of Science ®Google Scholar
• Ghazy RM , AlmaghrabyA, ShaabanRet al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci. Rep., 10(1), 22139 (2020).
   PubMed Web of Science ®Google Scholar
• Geleris J , SunY, PlattJet al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N. Engl. J. Med., 382(25), 2411–2418 (2020).
   PubMed Web of Science ®Google Scholar
• Rosenberg ES , DufortEM, UdoTet al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA, 323(24), 2493–2502 (2020).
   PubMed Web of Science ®Google Scholar
• Hussein RK , ElkhairHM. Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19. J. Mol. Struct., 1231, 129979 (2021).
   PubMed Web of Science ®Google Scholar
• Chowdhury MS , RathodJ, GernsheimerJ. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad. Emerg. Med., 27(6), 493–504 (2020).
   PubMed Web of Science ®Google Scholar
• Mahévas M , TranVT, RoumierMet al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. Medrxivhttps://doi.org/10.1101/2020.04.10.20060699 (2020) ( Epub ahead of print).
   Google Scholar
• Mahévas M , TranVT, RoumierMet al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, 369, m1844 (2020).
   PubMed Web of Science ®Google Scholar
• Skipper CP , PastickKA, EngenNWet al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann. Intern. Med., 173(8), 623–631 (2020).
   PubMed Web of Science ®Google Scholar
• Horby P , MafhamM, LinsellLet al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. MedRxivhttps://doi.org/10.1101/2020.07.15.20151852 (2020) ( Epub ahead of print).
   Google Scholar
• Patrì A , FabbrociniG. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and treatment?J. Am. Acad. Dermatol., 82(6), e221 (2020).
   PubMed Web of Science ®Google Scholar
• Mitjà O , Corbacho-MonnéM, UbalsMet al. A cluster-randomized trial of hydroxychloroquine for prevention of COVID-19. N. Engl. J. Med., 384(5), 417–427 (2021).
   PubMed Web of Science ®Google Scholar
• Boulware DR , PullenMF, BangdiwalaASet al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N. Engl. J. Med., 383(6), 517–525 (2020).
   PubMed Web of Science ®Google Scholar
• Tang W , CaoZ, HanMet al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 369, m1849 (2020).
   PubMed Web of Science ®Google Scholar
• Kamran SM , MoeedHA, MirzaZEet al. Clearing the fog: is hydroxychloroquine effective in reducing coronavirus disease-2019 progresression? A randomized controlled trial. Cureus, 13(3), e14186 (2021).
   PubMed Web of Science ®Google Scholar
• Ip A , AhnJ, ZhouYet al. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. BMC Infect. Dis., 21(1), 72 (2021).
   PubMed Web of Science ®Google Scholar
• Oymak Y , KarapinarTH, Devrimİ. Why G6PD deficiency should be screened before COVID-19 treatment with hydroxychloroquine?J. Pediatr. Hematol. Oncol., 43(1), 35–36 (2021).
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM , KashourZ, AldosaryOet al. Cardiac toxicity of chloroquine or hydroxychloroquine in patients with COVID-19: a systematic review and meta-regression analysis. Mayo Clin. Proc. Innov. Qual. Outcomes, 5(1), 137–150 (2021).
   PubMedGoogle Scholar
• Van den Broek MPH , MöhlmannJE, AbelnBGS, LiebregtsM, Van DijkVF, VanDe Garde EMW. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth. Heart J., 28(7–8), 406–409 (2020).
   PubMed Web of Science ®Google Scholar
• Vick DJ . Glucose-6-phosphate dehydrogenase deficiency and COVID-19 infection. Mayo Clin. Proc., 95(8), 1803–1804 (2020).
   PubMed Web of Science ®Google Scholar
• Chorin E , WadhwaniL, MagnaniSet al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm, 17(9), 1425–1433 (2020).
   PubMed Web of Science ®Google Scholar
• Song Y , ZhangM, YinLet al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int. J. Antimicrob. Agents, 56(2), 106080 (2020).
   PubMed Web of Science ®Google Scholar
• WHO . WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. http://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-COVID-19
   Google Scholar
• Ho TC , WangYH, ChenYLet al. Chloroquine and hydroxychloroquine: efficacy in the treatment of the COVID-19. Pathogens, 10(2), 217 (2021).
   PubMed Web of Science ®Google Scholar
• Parperis K . To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic. Ann. Rheum. Dis., 80(1), e8 (2021).
   PubMed Web of Science ®Google Scholar
• Li G , LiY, LiZ, ZengM. Artemisinin-based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them.Academic PressLondon, UK, 1–736 (2017).
   Google Scholar
• Romero MR , EfferthT, SerranoMAet al. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an “in vitro” replicative system. Antiviral Res., 68(2), 75–83 (2005).
   PubMed Web of Science ®Google Scholar
• Canivet C , MenasriaR, RhéaumeC, PiretJ, BoivinG. Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. Antiviral Res., 123, 105–113 (2015).
   PubMed Web of Science ®Google Scholar
• Efferth T , RomeroMR, WolfDG, StammingerT, MarinJJ, MarschallM. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis., 47(6), 804–811 (2008).
   PubMed Web of Science ®Google Scholar
• Drouot E , PiretJ, BoivinG. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir. Ther., 21(6), 535–539 (2016).
   PubMed Web of Science ®Google Scholar
• Dediego ML , Nieto-TorresJL, Regla-NavaJAet al. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol., 88(2), 913–924 (2014).
   PubMed Web of Science ®Google Scholar
• Lee JY , BaeS, MyoungJ. Middle East respiratory syndrome coronavirus-encoded accessory proteins impair MDA5-and TBK1-mediated activation of NF-κB. J. Microbiol. Biotechnol., 29(8), 1316–1323 (2019).
   PubMed Web of Science ®Google Scholar
• Brian DA , BaricRS. Coronavirus genome structure and replication. Curr. Top. Microbiol. Immunol., 287, 1–30 (2005).
   PubMed Web of Science ®Google Scholar
• Catanzaro M , FagianiF, RacchiM, CorsiniE, GovoniS, LanniC. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal. Transduct. Target Ther., 5(1), 84 (2020).
   PubMed Web of Science ®Google Scholar
• Xu H , HeY, YangXet al. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford), 46(6), 920–926 (2007).
   PubMed Web of Science ®Google Scholar
• Moore JB , JuneCH. Cytokine release syndrome in severe COVID-19. Science, 368(6490), 473–474 (2020).
   PubMed Web of Science ®Google Scholar
• Cao R , HuH, LiYet al. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect. Dis., 6(9), 2524–2531 (2020).
   PubMed Web of Science ®Google Scholar
• Nie C , TrimpertJ, MoonSet al. In vitro efficacy of Artemisia extracts against SARS-CoV-2. Virol. J., 18(1), 182 (2021).
   PubMed Web of Science ®Google Scholar
• Russo M , MocciaS, SpagnuoloC, TedescoI, RussoGL. Roles of flavonoids against coronavirus infection. Chem. Biol. Interact., 328, 109211 (2020).
   PubMed Web of Science ®Google Scholar
• Zhou Y , GilmoreK, RamirezSet al. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. Sci. Rep., 11(1), 14571 (2021).
   PubMed Web of Science ®Google Scholar
• Nair MS , HuangY, FidockDAet al. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants. J. Ethnopharmacol., 274, 114016 (2021).
   PubMed Web of Science ®Google Scholar
• Hu Y , LiuM, QinHet al. Artemether, artesunate, arteannuin B, echinatin, licochalcone B and andrographolide effectively inhibit SARS-CoV-2 and related viruses in vitro. Front. Cell. Infect. Microbiol., 11, 680127 (2021).
   PubMed Web of Science ®Google Scholar
• Krishna S , AugustinY, WangJet al. Repurposing antimalarials to tackle the COVID-19 pandemic. Trends Parasitol., 37(1), 8–11 (2021).
   PubMed Web of Science ®Google Scholar
• Uckun FM , SaundS, WindlassH, TrieuV. Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug. Front. Pharmacol., 12, 649532 (2021).
   PubMed Web of Science ®Google Scholar
• Fry MPM . Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4’-chlorophenyl) cyclohexyl]-3-hydroxy-1, 4-naphthoquinone (566C80). Biochem. Pharmacol., 43(7), 1545–1553 (1992).
   PubMed Web of Science ®Google Scholar
• Atovaquone and azithromycin combination for confirmed COVID-19 infection. NCT04339426. https://clinicaltrials.gov/ct2/show/NCT04339426
   Google Scholar
• Singh S , FlorezH. Coronavirus disease 2019 drug discovery through molecular docking. F1000Res, 9, 502 (2020).
   PubMedGoogle Scholar
• Farag A , WangP, BoysInet al. Identification of atovaquone, ouabain and mebendazole as FDA approved drugs targeting SARS-CoV-2 (version 4). ChemRxivhttps://doi.org/10.26434/chemrxiv.12003930.v4 (2021) ( Epub ahead of print).
   PubMedGoogle Scholar
• Marak BN , DowarahJ, KhiangteL, SinghVP. Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach. Drug Dev. Res., 82(3), 374–392 (2021).
   PubMed Web of Science ®Google Scholar
• Carter-Timofte ME , ArulanandamR, KurmashevaNet al. Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern. ACS Infect. Dis., 7(11), 3034–3051 (2021).
   PubMed Web of Science ®Google Scholar
• González Canga A , SahagúnPrieto AM, DiezLiébana MJ, FernándezMartínez N, SierraVega M, GarcíaVieitez JJ. The pharmacokinetics and interactions of ivermectin in humans – a mini-review. AAPS J, 10(1), 42–46 (2008).
   PubMed Web of Science ®Google Scholar
• Laing R , GillanV, DevaneyE. Ivermectin - old drug, new tricks?Trends Parasitol., 33(6), 463–472 (2017).
   PubMed Web of Science ®Google Scholar
• Azam F , TabanIM, EidEEMet al. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α. J. Biomol. Struct. Dyn., https://doi.org/10.1080/07391102.2020.18410281–14 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Azeem S , AshrafM, RasheedMA, AnjumAA, HameedR. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak. J. Pharm. Sci., 28(2), 597–602 (2015).
   PubMed Web of Science ®Google Scholar
• Chaccour C , HammannF, Ramón-GarcíaS, RabinovichNR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am. J. Trop. Med. Hyg., 102(6), 1156–1157 (2020).
   PubMed Web of Science ®Google Scholar
• Götz V , MagarL, DornfeldDet al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci. Rep., 6, 23138 (2016).
   PubMed Web of Science ®Google Scholar
• Lv C , LiuW, WangBet al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res., 159, 55–62 (2018).
   PubMed Web of Science ®Google Scholar
• Rizzo E . Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn Schmiedebergs Arch. Pharmacol., 393(7), 1153–1156 (2020).
   PubMed Web of Science ®Google Scholar
• Gupta D , SahooAK, SinghA. Ivermectin: potential candidate for the treatment of Covid 19. Braz. J. Infect. Dis., 24(4), 369–371 (2020).
   PubMed Web of Science ®Google Scholar
• Hashim HA , MauloodMF, RasheedAM, FatakDF, KabahKK, AbdulamirAS. Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. MedRxivhttps://doi.org/10.1101/2020.10.26.20219345 (2020) ( Epub ahead of print).
   Google Scholar
• Rajter JC , ShermanMS, FattehN, VogelF, SacksJ, RajterJJ. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study. Chest, 159(1), 85–92 (2021).
   PubMed Web of Science ®Google Scholar
• Rajter JC , ShermanMS, FattehN, VogelF, SacksJ, RajterJJ. ICON (ivermectin in covid nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19. Chest, 159(1), 85–92 (2021).
   PubMed Web of Science ®Google Scholar
• Ahmed S , KarimMM, RossAGet al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int. J. Infect. Dis., 103, 214–216 (2021).
   PubMed Web of Science ®Google Scholar
• López-Medina E , LópezP, HurtadoICet al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA, 325(14), 1426–1435 (2021).
   PubMed Web of Science ®Google Scholar
• Bryant A , LawrieTA, DowswellTet al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am. J. Ther., 28(4), e434–e460 (2021).
   PubMed Web of Science ®Google Scholar
• Kaur H , ShekharN, SharmaS, SarmaP, PrakashA, MedhiB. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol. Rep., 73(3), 736–749 (2021).
   PubMed Web of Science ®Google Scholar
• Ivermectin for COVID-19: real-time meta analysis of 65 studies. https://ivmmeta.com
   Google Scholar
• Altay O , MohammadiE, LamSet al. Current Status of COVID-19 therapies and drug repositioning applications. iScience, 23(7), 101303 (2020).
   PubMed Web of Science ®Google Scholar
• Haffizulla J , HartmanA, HoppersMet al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase IIb/III trial. Lancet Infect. Dis., 14(7), 609–618 (2014).
   PubMed Web of Science ®Google Scholar
• Rossignol JF . Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res., 110, 94–103 (2014).
   PubMed Web of Science ®Google Scholar
• Tilmanis D , Van BaalenC, OhDY, RossignolJF, HurtAC. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Res., 147, 142–148 (2017).
   PubMed Web of Science ®Google Scholar
• Rossignol JF . Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J. Infect. Public Health, 9(3), 227–230 (2016).
   PubMed Web of Science ®Google Scholar
• Calderón JM , ZerónHM, PadmanabhanS. Treatment with hydroxychloroquine vs hydroxychloroquine + nitazoxanide in COVID-19 patients with risk factors for poor prognosis: a structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), 504 (2020).
   PubMedGoogle Scholar
• Padmanabhan S , PadmanabhanK. “The devil is in the dosing” – targeting the interferon pathway by repositioning nitazoxanide against COVID-19. https://doi.org/10.13140/RG.2.2.22854.83527 (2020) ( Epub ahead of print).
   Google Scholar
• Hong SK , KimHJ, SongCS, ChoiIS, LeeJB, ParkSY. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. Int. Immunopharmacol., 13(1), 23–27 (2012).
   PubMed Web of Science ®Google Scholar
• Mehta P , McauleyDF, BrownM, SanchezE, TattersallRS, MansonJJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 395(10229), 1033–1034 (2020).
   PubMed Web of Science ®Google Scholar
• Miner K , LabitzkeK, LiuBet al. Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front. Pharmacol., 10, 51 (2019).
   PubMed Web of Science ®Google Scholar
• Rocco PRM , SilvaPL, CruzFFet al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur. Respir. J., 58(1), 2003725 (2021).
   PubMed Web of Science ®Google Scholar
• Elalfy H , BesheerT, El-MeseryAet al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J. Med. Virol., 93(5), 3176–3183 (2021).
   PubMed Web of Science ®Google Scholar
• Kelleni MT . NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown? .Inflammopharmacologyhttps://doi.org/10.1007/s10787-021-00896-7, 1–6 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Pepperrell T , PilkingtonV, OwenA, WangJ, HillAM. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. J. Virus Erad., 6(2), 52–60 (2020).
   PubMed Web of Science ®Google Scholar
• Rajoli RKR , PertinezH, ArshadUet al. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. Br. J. Clin. Pharmacol., 87(4), 2078–2088 (2021).
   PubMed Web of Science ®Google Scholar
• Blum VF , CimermanS, HunterJRet al. Nitazoxanide superiority to placebo to treat moderate COVID-19 – a pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine, 37, 100981 (2021).
   PubMedGoogle Scholar
• Cadegiani FA , GorenA, WambierCG, MccoyJ. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect., 43, 100915 (2021).
   PubMed Web of Science ®Google Scholar
• Olagunju A , FowotadeA, OlagunoyeAet al. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): a structured summary of a study protocol for a randomised controlled trial. Trials, 22(1), 3 (2021).
   PubMedGoogle Scholar
• Sayed AM , KhalafAM, AbdelrahimMEA, ElgendyMO. Repurposing of some anti-infective drugs for COVID-19 treatment: a surveillance study supported by an in silico investigation. Int. J. Clin. Pract., 75(4), e13877 (2021).
   PubMed Web of Science ®Google Scholar
• MendietaZerón H , MenesesCalderón J, PaniaguaCoria Let al. Nitazoxanide as an early treatment to reduce the intensity of COVID-19 outbreaks among health personnel. World Acad. Sci. J., 3(3), 23 (2021).
   Google Scholar
• Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. MedRxivhttps://doi.org/10.1101/2021.03.03.21252509 (2021) ( Epub ahead of print).
   Google Scholar
• Chen W , MookRAJr, PremontRT, WangJ. Niclosamide: beyond an antihelminthic drug. Cell. Signal., 41, 89–96 (2018).
   PubMed Web of Science ®Google Scholar
• Xu M , LeeEM, WenZet al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med., 22(10), 1101–1107 (2016).
   PubMed Web of Science ®Google Scholar
• Wu CJ , JanJT, ChenCMet al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother., 48(7), 2693–2696 (2004).
   PubMed Web of Science ®Google Scholar
• Xu J , ShiPY, LiH, ZhouJ. Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect. Dis., 6(5), 909–915 (2020).
   PubMed Web of Science ®Google Scholar
• Ko M , ChangSY, ByunSYet al. Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. Viruses, 13(4), 651(2021).
   PubMed Web of Science ®Google Scholar
• Romani D , NoureddineO, IssaouiN, BrandánSA. Properties and reactivities of niclosamide in different media, a potential antiviral to treatment of COVID-19 by using DFT calculations and molecular docking. Biointerface Res. Appl. Chem, 10(6), 7295–7328 (2020).
   Web of Science ®Google Scholar
• Gao K , NguyenDD, ChenJ, WangR, WeiGW. Repositioning of 8565 existing drugs for COVID-19. J. Phys. Chem. Lett., 11(13), 5373–5382 (2020).
   PubMed Web of Science ®Google Scholar
• Pindiprolu S , PindiproluSH. Plausible mechanisms of niclosamide as an antiviral agent against COVID-19. Med. Hypotheses, 140, 109765 (2020).
   PubMed Web of Science ®Google Scholar
• Gassen NC , PapiesJ, BajajTet al. Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics. BioRxivhttps://doi.org/10.1101/2020.04.15.9972542020.2004.2015.997254 (2020) ( Epub ahead of print).
   Google Scholar
• Das S , SarmahS, LyndemS, SinghaRoy A. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J. Biomol. Struct. Dyn., 39(9), 3347–3357 (2021).
   PubMed Web of Science ®Google Scholar
• Backer V , SjöbringU, SonneJet al. A randomized, double-blind, placebo-controlled phase I trial of inhaled and intranasal niclosamide: a broad spectrum antiviral candidate for treatment of COVID-19. Lancet Reg. Health Eur., 4, 100084 (2021).
   PubMedGoogle Scholar
• Pascoalino BS , CourtemancheG, CordeiroMT, GilLH, Freitas-JuniorL. Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library. F1000Res, 5, 2523 (2016).
   PubMedGoogle Scholar
• Tonelli M , SimoneM, TassoBet al. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. Bioorg. Med. Chem., 18(8), 2937–2953 (2010).
   PubMed Web of Science ®Google Scholar
• Farag A , WangP, BoysINet al. Identification of atovaquone, ouabain and mebendazole as FDA approved drugs targeting SARS-CoV-2 (Version 4). Chemrxivhttps://doi.org/10.26434/chemrxiv.12003930.v4 (2020) ( Epub ahead of print).
   Google Scholar
• Wang Z , GuoK, GaoPet al. Identification of repurposable drugs and adverse drug reactions for various courses of COVID-19 based on single-cell RNA sequencing data. ArXiv, 2005.07856v2 (2020) ( Epub ahead of print).
   Google Scholar
• Law JN , AkersK, TasninaNet al. Interpretable network propagation with application to expanding the repertoire of human proteins that interact with SARS-CoV-2. GigaSci., 10(12), https://doi.org/10.1093/gigascience/giab082 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Hajjo R , TropshaA. A systems biology workflow for drug and vaccine repurposing: identifying small-molecule BCG mimics to reduce or prevent COVID-19 mortality. Pharm. Res., 37(11), 212 (2020).
   PubMed Web of Science ®Google Scholar
• Repurposed antiviral drugs for COVID-19 – interim WHO solidarity trial results. N. Engl. J. Med., 384(6), 497–511 (2020).
   PubMed Web of Science ®Google Scholar
• Chan HCS , ShanH, DahounT, VogelH, YuanS. Advancing drug discovery via artificial intelligence. Trends Pharmacol. Sci., 40(8), 592–604 (2019).
   PubMed Web of Science ®Google Scholar
• Alsafi MA , HughesDL, SaidMA. First COVID-19 molecular docking with a chalcone-based compound: synthesis, single-crystal structure and Hirshfeld surface analysis study. Acta Crystallogr. C Struct. Chem., 76(Pt 12), 1043–1050 (2020).
   PubMedGoogle Scholar
• Barros RO , JuniorF, PereiraWS, OliveiraNMN, RamosRM. Interaction of drug candidates with various SARS-CoV-2 receptors: an in silico study to combat COVID-19. J. Proteome Res., 19(11), 4567–4575 (2020).
   PubMed Web of Science ®Google Scholar
• Hall DC Jr , JiHF. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med. Infect. Dis., 35, 101646 (2020).
   PubMed Web of Science ®Google Scholar
• Keshavarzi Arshadi A , WebbJ, SalemMet al. Artificial intelligence for COVID-19 drug discovery and vaccine development. Front. Artif. Intell., 3, 65 (2020).
   PubMedGoogle Scholar
• Peele KA , PotlaDurthi C, SrihansaTet al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: a computational study. Inform. Med. Unlocked, 19, 100345 (2020).
   PubMedGoogle Scholar
• Podlogar BL , MueggeI, BriceLJ. Computational methods to estimate drug development parameters. Curr. Opin. Drug Discov. Devel., 4(1), 102–109 (2001).
   PubMedGoogle Scholar
• Lestari K , SitorusT, InstiatyMegantara S, LevitaJ. Molecular docking of quinine, chloroquine and hydroxychloroquine to angiotensin converting enzyme 2 (ACE2) receptor for discovering new potential COVID-19 antidote. J. Adv. Pharm. Res., 10(2), 1–4 (2020).
   Google Scholar
• Shoichet BK . Virtual screening of chemical libraries. Nature, 432(7019), 862–865 (2004).
   PubMed Web of Science ®Google Scholar
• Melville JL , BurkeEK, HirstJD. Machine learning in virtual screening. Comb. Chem. High Throughput Screen, 12(4), 332–343 (2009).
   PubMed Web of Science ®Google Scholar
• Carpenter KA , HuangX. Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: a review. Curr. Pharm. Des., 24(28), 3347–3358 (2018).
   PubMed Web of Science ®Google Scholar
• Zhong F , XingJ, LiXet al. Artificial intelligence in drug design. Sci. China Life Sci., 61(10), 1191–1204 (2018).
   PubMed Web of Science ®Google Scholar
• Ahuja AS , ReddyVP, MarquesO. Artificial intelligence and COVID-19: a multidisciplinary approach. Integr. Med. Res., 9(3), 100434 (2020).
   PubMed Web of Science ®Google Scholar
• Pires C . A systematic review on the contribution of artificial intelligence in the development of medicines for COVID-2019. J. Pers. Med., 11(9), (2021).
   Web of Science ®Google Scholar
• Ke YY , PengTT, YehTKet al. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed. J., 43(4), 355–362 (2020).
   PubMed Web of Science ®Google Scholar
• Kowalewski J , RayA. Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space. Heliyon, 6(8), e04639 (2020).
   PubMed Web of Science ®Google Scholar
• Avchaciov K , BurmistrovaO, FedichevP. AI for the repurposing of approved or investigational drugs against COVID-19. ScienceOPENhttps://doi.org/10.13140/RG.2.2.20588.10886 (2020) ( Epub ahead of print).
   Google Scholar
• Gysi Dm DVÍ , ZitnikMet al. Proceedings of the national academy of sciences network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc. Natl Acad. Sci., 118(19), (2021).
   Web of Science ®Google Scholar
• Moskal M , BekerW, RoszakRet al. Suggestions for second-pass anti-COVID-19 drugs based on the artificial intelligence measures of molecular similarity, shape and pharmacophore distribution. ChemRxivhttps://doi.org/10.26434/chemrxiv.12084690.v2 (2020) ( Epub ahead of print).
   Google Scholar
• Richardson P , GriffinI, TuckerCet al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, 395(10223), e30–e31 (2020).
   PubMed Web of Science ®Google Scholar
• Stebbing J , PhelanA, GriffinIet al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis., 20(4), 400–402 (2020).
   PubMed Web of Science ®Google Scholar
• Kalil AC , PattersonTF, MehtaAKet al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med., 384(9), 795–807 (2021).
   PubMed Web of Science ®Google Scholar
• Marconi VC , RamananAV, DeBono Set al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase III trial. Lancet Respir. Med., 9(12), 1407–1418 (2021).
   PubMed Web of Science ®Google Scholar
• Stebbing J , SánchezNievas G, FalconeMet al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci. Adv., 7(1), eabe4724 (2021).
   PubMed Web of Science ®Google Scholar
• Savage N . Tapping into the drug discovery potential of AI. http://www.nature.com/articles/d43747-021-00045-7
   Google Scholar
• Zhavoronkov A , VanhaelenQ, OpreaTI. Will artificial intelligence for drug discovery impact clinical pharmacology?Clin. Pharmacol. Ther., 107(4), 780–785 (2020).
   PubMed Web of Science ®Google Scholar
• Bhhatarai B , WaltersWP, HopC, LanzaG, EkinsS. Opportunities and challenges using artificial intelligence in ADME/Tox. Nat. Mater., 18(5), 418–422 (2019).
   PubMed Web of Science ®Google Scholar
• Bullock J , LuccioniA, PhamKH, LamCSN, Luengo-OrozM. Mapping the landscape of artificial intelligence applications against COVID-19. J. Artif. Intell. Res., 69, 807–845 (2020).
   Web of Science ®Google Scholar